Need professional-grade analysis? Visit stockanalysis.com
$106.28M
N/A
103
N/A
Crossject (ALCJ) trades on Euronext Paris in EUR. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at EUR1.99, down 0.75% from the previous close.
Over the past year, ALCJ has traded between a low of EUR0.86 and a high of EUR2.69. The stock has gained 124.5% over this period. It is currently 26.0% below its 52-week high.
Crossject has a market capitalization of $106.28M.
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Side-by-side comparison against top Healthcare peers.